Indication
Paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells primarily affecting the hematologic and vascular systems in adults. Read more about Paroxysmal nocturnal hemoglobinuria
9 drugs 7 manufacturers
Drugs that treat it
Common Paroxysmal nocturnal hemoglobinuria therapies.
ULTOMIRIS (ravulizumab-cwvz)
EMPAVELI (pegcetacoplan)
FABHALTA (iptacopan HCl)
VOYDEYA (danicopan)
PIASKY (crovalimab-akkz)
BKEMV (eculizumab-aeeb)
EPYSQLI (eculizumab-aagh)
FABHALTA (iptacopan HCl)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonParoxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells primarily affecting the hematologic and vascular systems in adults.
It is caused by somatic mutations in the X-linked *PIGA* gene, which leads to a deficiency of glycosylphosphatidylinositol (GPI) anchors and the subsequent loss of surface complement regulatory proteins, notably CD55 and CD59.
This absence leaves erythrocytes vulnerable to unchecked complement-mediated destruction, driving chronic intravascular hemolysis.
Clinically, the disease is characterized by a classic triad of hemolytic anemia, an elevated propensity for venous and arterial thrombosis, and varying degrees of bone marrow failure, often presenting with hemoglobinuria, fatigue, and organ damage.
- nih.gov
Paroxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells primarily affecting the hematologic and vascular systems in adults It is caused by somatic mutations in the X-linked *PIGA* gene, which leads to a deficiency of glycosylphosphatidylinositol (GPI) anchors and the subsequent loss of surface complement regulatory proteins, notably CD55 and CD59 This absence leaves erythrocytes vulnerable to unchecked complement-mediated destruction, driving chronic i...
- nih.gov
Paroxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells primarily affecting the hematologic and vascular systems in adults Clinically, the disease is characterized by a classic triad of hemolytic anemia, an elevated propensity for venous and arterial thrombosis, and varying degrees of bone marrow failure, often presenting with hemoglobinuria, fatigue, and organ damage
- nih.gov
It is caused by somatic mutations in the X-linked *PIGA* gene, which leads to a deficiency of glycosylphosphatidylinositol (GPI) anchors and the subsequent loss of surface complement regulatory proteins, notably CD55 and CD59 This absence leaves erythrocytes vulnerable to unchecked complement-mediated destruction, driving chronic intravascular hemolysis
Personalize your experience
Follow Paroxysmal nocturnal hemoglobinuria and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.